Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus, which
is widely distributed in the intestinal tract of humans and animals and in the environment. In …

Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent
Clostridioides difficile infection. FMT has become a more readily available and useful new …

Importance A safe and effective treatment for recurrentClostridioides difficileinfection (CDI) is
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

AIM To perform a systematic review and meta-analysis on proton pump inhibitors (PPIs)
therapy and the risk of Clostridium difficile infection (CDI). METHODS We conducted a …

The most common cause of antibiotic-associated diarrhea is Clostridium difficile infection
(CDI). Recurrent C. difficile infection (rCDI) often occurs after successful treatment of CDI …

Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile
toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk …

In the last three decades, Clostridium difficile infection (CDI) has increased in incidence and
severity in many countries worldwide. The increase in CDI incidence has been particularly …

Background: Clostridium difficile infection (CDI), the most common health care–associated
infection, often recurs. Fecal microbiota transplantation is increasingly used to treat multiply …

Background Recognition of a broad spectrum of disease and development of Clostridium
difficile infection (CDI) and recurrent CDI (rCDI) in populations previously considered to be …